Skip to main content

Table 1 Main characteristics of patients receiving ovarian stimulation by highly purified urinary human follicle stimulating hormone (HP-uFSH) or recombinant human follicle stimulating hormone (rFSH) (* values are expressed as mean ± SD; ns = not significant)

From: Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-FSH vs. HP-uFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis

 

Overall

HP-uFSH

rFSH

p

N. of patients

260

130

130

 

Age (years) *

32.7 ± 4.3

33.0 ± 3.6

32.3 ± 4.0

ns

BMI (kg/m2) *

21.5 ± 3.4

21.2 ± 3.0

21.3 ± 3.1

ns

Duration of infertility (years) *

2.6 ± 1.5

2.7 ± 1.4

2.5 ± 1.4

ns

Type of infertility (%):

    

   Primary

196

97 (74.6)

99 (76.1)

ns

   Secondary

64

33 (25.4)

31 (23.9)

ns

Indication to treatment (%):

    

   unexplained infertility

184

91 (70.0)

93 (71.5)

ns

   CC-resistant PCOS

76

39 (30.0)

37 (28.5)

ns

LH/FSH *

1.4 ± 0.6

1.3 ± 0.9

1.4 ± 0.9

ns

Testosterone (ng/mL) *

0.6 ± 0.8

0.6 ± 0.5

0.7 ± 0.1

ns

Prolactin (ng/mL) *

17.9 ± 4.1

17.7 ± 4.0

18.3 ± 3.8

ns